- $5.43bn
- $5.62bn
- $1.24bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 5.98 | ||
| PEG Ratio (f) | 0.86 | ||
| EPS Growth (f) | 7.47% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 187.38 | ||
| Price to Sales | 3.95 | ||
| EV to EBITDA | 10.27 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1741.94% | ||
| Return on Equity | n/a | ||
| Operating Margin | 39.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 791 | 901 | 1,093 | 1,188 | 1,239 | 1,320.35 | 1,381.58 | 13.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +67.67 | -31.14 | +37.56 | -20.01 | +64.61 | +121.92 | -1.49 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Supernus, Inc., formerly Indivior Pharmaceuticals, Inc., is a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. The Company's commercial platform offers various product portfolios consisting of opioid use disorder, psychiatry, and neurology, and includes five core growth drivers, including SUBLOCADE, Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE. Its portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
Directors
- Keith Humphreys NID (59)
- Tony Kingsley NEC (62)
- Jack Khattar CEO (65)
- Timothy Dec CFO (68)
- Frank Mottola COO (54)
- Padmanabh Bhatt SVP (69)
- Bryan Roecklein SVP
- William Horich SVP (54)
- Jonathan Rubin SVP (65)
- Georges Gemayel DRC (66)
- Carrolee Barlow DRC (63)
- Bethany Sensenig DRC (51)
- Last Annual
- December 31st, 2025
- Last Interim
- September 30th, 2026
- Incorporated
- October 28th, 2025
- Public Since
- June 12th, 2023
- No. of Shareholders
- 139
- No. of Employees
- 827
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 207,724,098
- Address
- 9715 Key West Avenue, ROCKVILLE, 20850
- Web
- https://www.indivior.com
- Phone
- +1 8043791090
- Contact
- Jason Thompson
- Auditors
- PricewaterhouseCoopers LLP
Latest News for SUPN
Upcoming Events for SUPN
Similar to SUPN
Alkermes
NASDAQ Global Select Market
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 22:34 UTC, shares in Supernus are trading at $26.16. This share price information is delayed by 15 minutes.
Shares in Supernus last closed at $26.16 and the price had moved by +5.79% over the past 365 days. In terms of relative price strength the Supernus share price has underperformed the S&P500 Index by -3.5% over the past year.
The overall consensus recommendation for Supernus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSupernus does not currently pay a dividend.
Supernus does not currently pay a dividend.
Supernus does not currently pay a dividend.
To buy shares in Supernus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $26.16, shares in Supernus had a market capitalisation of $5.43bn.
Here are the trading details for Supernus:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SUPN
Based on an overall assessment of its quality, value and momentum Supernus is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Supernus is $50.25. That is 92.09% above the last closing price of $26.16.
Analysts covering Supernus currently have a consensus Earnings Per Share (EPS) forecast of $4.43 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Supernus. Over the past six months, its share price has underperformed the S&P500 Index by -14.23%.
As of the last closing price of $26.16, shares in Supernus were trading -5.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Supernus PE ratio based on its reported earnings over the past 12 months is 5.98. The shares last closed at $26.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Supernus' management team is headed by:
- Keith Humphreys - NID
- Tony Kingsley - NEC
- Jack Khattar - CEO
- Timothy Dec - CFO
- Frank Mottola - COO
- Padmanabh Bhatt - SVP
- Bryan Roecklein - SVP
- William Horich - SVP
- Jonathan Rubin - SVP
- Georges Gemayel - DRC
- Carrolee Barlow - DRC
- Bethany Sensenig - DRC